- Low-quality evidence suggests that stem cell therapy reduces the risk for all-cause mortality at long-term follow-up in people with chronic ischaemic heart disease (CIHD), heart failure (HF) secondary to ischaemic heart disease and refractory angina.
Why this matters
- Recent trials investigating the use of cell therapies for CIHD and HF have shown conflicting results.
- Pooled results showed that cell therapy was associated with reduction in long-term incidence of:
— Mortality (≥12 mo) (risk ratio [RR], 0.42; participants, 491; studies, 9).
— Non-fatal myocardial infarction (RR, 0.38; participants, 345; studies, 5).
— Arrhythmias (RR, 0.42; participants, 82; studies, 1).
- There was no evidence that cell therapy affects the risk for:
— Rehospitalisation for HF (RR, 0.63; participants, 375; studies, 6).
— Composite incidence of mortality, non-fatal myocardial infarction and rehospitalisation for HF (RR, 0.64; participants, 141; studies, 3).
— Long-term left ventricular ejection fraction (mean difference, -1.60; participants, 25; studies, 1).
- 38 randomised controlled trials covering 1907 participants (1114 cell therapy; 793 control participants) met eligibility criteria after a review on CENTRAL, MEDLINE, Embase, LILACS, CINAHL and various other resources.
- Funding: None.
- Low-quality evidence.
- High risk for selection bias.